Johan Skog is a renowned, well-published thought leader in exosome science having pioneered breakthrough discoveries about exosomes and other micro vesicles and their vital role as cell messengers and disease proliferators. While at Massachusetts General Hospital/Harvard Medical School, Dr. Skog discovered that tumor-derived mutations can be detected in exosome RNA from serum and other biofluids, findings which were published in Nature Cell Biology in 2008. Additionally, he demonstrated that exosomes serve to deliver messages to other cells, inducing changes favorable to the proliferation of cancer. Dr. Skog is the inventor of several novel exosome isolation platforms that are used clinically and has over 138 applications/divisional/or granted patents in the exosome field. He continues to expand the research on exosome biology and lead critical advancements in diagnostics, including the world’s first exosome-based diagnostic tests that have now helped over 60,000 patients.
Clinical Dx Showcase:
Exosome Diagnostics, a Bio-Techne brand, is a world leader in developing liquid biopsy-based diagnostics.with clinical laboratories in Waltham, MA (US) and Munich (DE) to support its diagnostics and biopharma segments.
Exosomes: New Standard In Multi-Analyte Liquid Biopsy Testing
The PMWC 2022 Data Applications in Clinical Diagnostics Showcase will provide a 15-minute time slot for selected organizations, including commercial companies, clinical testing labs, and medical research institutions, to present their latest advancements, insights, applications, and technologies to an audience of clinicians, leading investigators, academic institutions, pharma and biotech, investors, and potential clients. We will learn about new technologies and findings that promise expedited, cost-effective, and accurate clinical diagnosis for early disease detection, treatment decisions, and disease prevention.
- Clinical Dx/Oncology (including Liquid Biopsy)
- Clinical Dx/Cardio Vascular
- Clinical Dx/Nerodegenerative